8-800-600-90-77
(From 9:00 till 18:00)
(From 9:00 till 18:00)
Reagent ELISA "SARS-CoV-2 IgM / IgG Screen"
Diagnosis of COVID-19 in Patients with Acute Respiratory Syndrome
Identification of asymptomatic and erased forms of COVID-19 in the foci of the disease, examination of those in contact with infected SARS-CoV-2
Examination of persons arriving from regions with a high level of COVID-19 disease and their re-examination before leaving the observation
Identification of COVID-19 patients, regardless of the form of the infectious process
Identification of potential donors of high-titer plasma that can be used in the treatment of severe forms of COVID-19
RU, RZN2020 / 11864 on the territory of the Russian Federation
Identification of asymptomatic and erased forms of COVID-19 in the foci of the disease, examination of those in contact with infected SARS-CoV-2
Examination of persons arriving from regions with a high level of COVID-19 disease and their re-examination before leaving the observation
Identification of COVID-19 patients, regardless of the form of the infectious process
Identification of potential donors of high-titer plasma that can be used in the treatment of severe forms of COVID-19
RU, RZN2020 / 11864 on the territory of the Russian Federation
Scope of the "SARS-CoV-2 IgM / IgG Screen" reagent ELISA
SARS-CoV-2 IgM / IgG Screen" reagents set (diagnosis of COVID-19) is significantly cheaper than molecular tests and can be used for large-scale studies to determine the true lethality and dynamics of the spread of SARS-CoV-2, which will contain the spread of the pathogen COVID -19 after the termination of quarantine measures.
Microplate 96-well polystyrene, dismountable, ready to use. Recombinant antigen, identical in immunological properties to Spike-Glycoproteid (S) SARS-CoV-2, immobilized on the inner surface of the microplate wells - 1 pc.
Negative control - based on human serum, does not contain IgG and IgM antibodies to Spike-Glycoproteid (S) SARS-CoV-2, ready for use
Positive control - based on human serum, contains IgG and IgM antibodies to Spike-Glycoproteid (S) SARS-CoV-2, ready for use
Sample dilution solution, ready to use.
Concentrate conjugate - a mixture of mouse monoclonal antibodies to human IgG and IgM conjugated with horseradish peroxidase.
Conjugate dilution solution.
TMB concentrate.
Solution for diluting TMB.
Wash solution concentrate.
Stop reagent, ready to use.
Film for tablet - 3 pcs.
Negative control - based on human serum, does not contain IgG and IgM antibodies to Spike-Glycoproteid (S) SARS-CoV-2, ready for use
Positive control - based on human serum, contains IgG and IgM antibodies to Spike-Glycoproteid (S) SARS-CoV-2, ready for use
Sample dilution solution, ready to use.
Concentrate conjugate - a mixture of mouse monoclonal antibodies to human IgG and IgM conjugated with horseradish peroxidase.
Conjugate dilution solution.
TMB concentrate.
Solution for diluting TMB.
Wash solution concentrate.
Stop reagent, ready to use.
Film for tablet - 3 pcs.
Set "SARS-CoV-2 IgM / IgG Screen" (diagnostics of COVID-19) consists of:
Initially, the fact of infection with SARS-CoV-2 was confirmed by the identification of the RNK of the pathogen. Now these tests are widely used and are represented by sets of both foreign and domestic production. Test systems of the PCR-Rt and LAMP format (loop isothermal amplification) are mainly used. But, unfortunately, molecular research methods, despite their high analytical characteristics, have a number of disadvantages.
First, the sensitivity and specificity of molecular methods in practice is often lower than the test manufacturers claim. This is due to the significant influence on the reliability of the study of the method, place and time of taking the material, the staff qualifications.
Secondly, the amount of RNA of the pathogen in the sample may be less than the test sensitivity threshold
Thirdly, molecular methods are quite expensive, in most cases they require special equipment and trained personnel. This significantly limits the possibilities of their mass use.
Fourthly, molecular methods cannot be used to identify those who have already had COVID-19 in order to fully analyze the epidemic process.
First, the sensitivity and specificity of molecular methods in practice is often lower than the test manufacturers claim. This is due to the significant influence on the reliability of the study of the method, place and time of taking the material, the staff qualifications.
Secondly, the amount of RNA of the pathogen in the sample may be less than the test sensitivity threshold
Thirdly, molecular methods are quite expensive, in most cases they require special equipment and trained personnel. This significantly limits the possibilities of their mass use.
Fourthly, molecular methods cannot be used to identify those who have already had COVID-19 in order to fully analyze the epidemic process.
Kindly leave your email and we will
reply to your interested questions
reply to your interested questions
Navigation
Contact us
Russian Federation,
Novosibirsk region,
w.s. Koltsovo, st. Sadovaya, 2/7
Novosibirsk region,
w.s. Koltsovo, st. Sadovaya, 2/7
Working hours: Mon.-Fri
9:00 a.m. - 8:00 p.m.
9:00 a.m. - 8:00 p.m.
8-800-600-90-77
info@imbian.ru
